Optiscan continues to generate sales of its flexible endo-microscope, while clinical trial success of its rigid version potentially opens up new opportunities.
ABN Amro Morgans rates both Peplin and Ventracor as Buys, expecting both stocks to enjoy positive news flow in coming months thanks to successful trial results and growing product awareness.
Bank of Queensland’s profit result was better than the market has expected, but brokers continue to view the stock as overpriced.
Employment grew again last month, lending weight to RBA governor Glenn Stevens’ arguments yesterday regarding the economy, and to chances of a November hike.
Merrill Lynch has lifted its earnings estimates for BHP and Rio thanks to increases to iron ore price forecasts, while Citigroup suggests exploration success offers valuation upside.
The proposed 2/3 rule and content obligations will reduce the number of companies likely to be players in the pending media consolidation rush.
The risks in the US housing market are still to the downside and the same still applies for Rinker, James Hardie and Boral, says Credit Suisse.
Two interest rate hikes are not enough to put a serious dent in Aussie consumer confidence, the latest survey by Westpac and the Melbourne Institute has found.
Citigroup expects Macquarie Infrastructure shares will rally if sale proceeds from the US assets are used for a share buyback.
Are resources stocks on the verge of their second wind? The institutional desk at GSJBW seems to think so.